MAGELLAN LONGEVITY
HomeResearchStudy library › Is zinc effective in reducing the incidence, severity, and duration…
Study summary · Nutrition, micronutrients & whole foods

Is zinc effective in reducing the incidence, severity, and duration of common cold symptoms, and what are the potential sources of heterogeneity in study results?

In one paragraph

Zinc Picolinate, a randomized, double-blind, placebo-controlled trial (Cochrane Database Syst Rev 2013, PMID 23775705) — zinc intake was associated with a significant reduction in the duration of common cold symptoms (mean difference -1.03 days) and a smaller proportion of participants symptomatic after seven days (odds ratio 0.45). The very high heterogeneity across the included studies means that the averaged estimates should be viewed with caution.

Source: Cochrane Database Syst Rev 2013, PMID 23775705 ↗ · Research map · How Magellan grades evidence · evidence confidence: high

Cochrane Database Syst Rev · 2013 · PMID 23775705 · DOI 10.1002/14651858.CD001364.pub4

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

Zinc may shorten the duration of common cold symptoms if taken early at a dose of ≥ 75 mg/day, but it can cause side effects like bad taste and nausea.

The question

Is zinc effective in reducing the incidence, severity, and duration of common cold symptoms, and what are the potential sources of heterogeneity in study results?

What they tested

The study aims to assess the efficacy of zinc in reducing common cold symptoms and identify factors influencing study outcomes.

How they did it

This updated systematic review searched multiple databases for randomized, double-blind, placebo-controlled trials. Trials included used zinc for at least five consecutive days for treatment or five months for prevention of the common cold. Two authors independently extracted data and assessed trial quality.

What they found

The review included 16 therapeutic trials (1387 participants) and two preventive trials (394 participants). Zinc intake was associated with a significant reduction in the duration of common cold symptoms (mean difference -1.03 days) and a smaller proportion of participants symptomatic after seven days (odds ratio 0.45). The incidence rate of developing a cold (IRR 0.64), school absence, and antibiotic prescriptions were lower in the zinc group. However, zinc was not associated with a significant reduction in symptom severity. Adverse events, including bad taste (OR 2.31) and nausea (OR 2.15), were higher in the zinc group. High heterogeneity was observed across results.

Impact of Zinc on Common Cold Symptoms and Side Effects
Values shown: Mean Difference or Odds Ratio
Duration of Cold (days)-1.03
Symptomatic after 7 days (OR)0.45
Incidence of Cold (IRR)0.64
Overall Adverse Events (OR)1.58
Bad Taste (OR)2.31
Nausea (OR)2.15

Zinc significantly reduced the duration of common cold symptoms and the proportion of symptomatic individuals after 7 days, as well as the incidence of colds. However, it also increased the occurrence of overall adverse events, bad taste, and nausea.

What it means

Zinc administered within 24 hours of symptom onset reduces the duration of common cold symptoms in healthy individuals, but data heterogeneity requires caution. For treatment, zinc lozenges at a dose of ≥ 75 mg/day are suggested. No firm recommendation can be made for prophylactic zinc due to insufficient data. The benefits of zinc lozenges must be weighed against side effects like bad taste and nausea.

Limitations

The very high heterogeneity across the included studies means that the averaged estimates should be viewed with caution. Insufficient data prevented a firm recommendation for prophylactic zinc supplementation.

“zinc was associated with a significant reduction in the duration of common cold symptoms”— from the published abstract, Cochrane Database Syst Rev 2013

The paper at a glance

Magellan’s evidence labelcatalytic/structural cofactor, immunity (our label for this citation — see PubMed for the paper’s own title and authors)
JournalCochrane Database Syst Rev
Year2013
PMID23775705 ↗
DOI10.1002/14651858.CD001364.pub4 ↗
TopicNutrition, micronutrients & whole foods

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

Zinc Picolinate

Multiple meta-analyses of randomized trials indicate that oral zinc, started soon after symptom onset, can modestly shorten the duration of common-cold symptoms, although a 2024 Cochrane update rated the certainty of this evidence low and the effect remains genuinely contested.

Zinc Picolinate

Zinc picolinate is a chelated form of the essential trace mineral zinc, in which zinc is bound to…

Check price on Amazon ↗

Research describes the compound or intervention studied. It is not a claim about any specific product.

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). Is zinc effective in reducing the incidence, severity, and duration of common cold symptoms, and what are the potential sources of heterogeneity in study results? [Plain-English summary of Cochrane Database Syst Rev 2013, PMID 23775705, DOI 10.1002/14651858.CD001364.pub4]. Magellan Longevity. https://magellanlongevity.com/study/s133.html
BibTeX
@misc{magellan_s133, title = {Is zinc effective in reducing the incidence, severity, and duration of common cold symptoms, and what are the potential sources of heterogeneity in study results?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/s133.html}}, note = {Plain-English summary of PubMed PMID 23775705; DOI 10.1002/14651858.CD001364.pub4; Cochrane Database Syst Rev 2013. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/s133.html

Related studies in the Magellan library

All 7 Magellan summaries on nutrition, micronutrients & whole foods →

How this summary was made. Every section above restates what the published abstract of PMID 23775705 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.